文献速递脑血管病

缺血性卒中合并心房颤动后启动直接口服抗凝药的实用「1-2-3-4天」规则:基于医院的前瞻性队列联合研究

Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study.
PubMed 文献 · Stroke · 2022-02-02

基于日本两项前瞻性注册研究(Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-nonvalvular atrial fibrillation与RELAXED)的1797例患者数据,按卒中严重程度分层,发现短暂性脑缺血发作后中位2天、轻型卒中后3天、中型卒中后4天、重型卒中后5天启动直接口服抗凝药;早期启动组(n=785)较晚期启动组(n=1012)的卒中或系统性栓塞复合终点更低(1.9% vs 3.9%;校正风险比0.50,95%CI 0.27-0.89),缺血性卒中亦更低(1.7% vs 3.2%,0.54,0.27-0.999),大出血两组相似(0.8% vs 1.0%)。欧洲六项前瞻性注册研究验证显示早期组与晚期组缺血性卒中(2.4% vs 2.2%)和颅内出血(0.2% vs 0.6%)相似。

要点

  • 按卒中严重程度分层,短暂性脑缺血发作后中位2天、轻型卒中3天、中型卒中4天、重型卒中5天启动直接口服抗凝药。
  • 早期启动组卒中或系统性栓塞复合终点1.9% vs 晚期组3.9%,校正风险比0.50(95%CI 0.27-0.89)。
  • 早期启动组缺血性卒中1.7% vs 晚期组3.2%(0.54,0.27-0.999),大出血两组相似(0.8% vs 1.0%)。

核心结论

  • 在日本和欧洲人群中,根据卒中严重程度在1、2、3或4天内早期启动直接口服抗凝药似乎可行,可降低复发性卒中或系统性栓塞风险且不增加大出血。
  • 这些发现支持正在进行的随机试验以更好地确定直接口服抗凝药启动的最佳时机。

研究设计与样本

  • 联合日本两项前瞻性注册研究(Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-nonvalvular atrial fibrillation,2011年9月至2014年3月;RELAXED,2014年2月至2016年4月)的数据,推导队列1797例。
  • 按美国国立卫生研究院卒中量表评分分为短暂性脑缺血发作及轻型(0-7分)、中型(8-15分)、重型(≥16分)卒中亚组。
  • 早期治疗组定义为在各亚组中启动直接口服抗凝药早于中位启动天数的患者。
  • 使用欧洲六项前瞻性注册研究进行验证。

主要发现

  • 推导队列1797例中,短暂性脑缺血发作后中位2天、轻型卒中后3天、中型卒中后4天、重型卒中后5天启动直接口服抗凝药。
  • 早期组(n=785,分别在1、2、3、4天内启动)较晚期组(n=1012)卒中或系统性栓塞更少(1.9% vs 3.9%;校正风险比0.50,95%CI 0.27-0.89)。
  • 早期组缺血性卒中更少(1.7% vs 3.2%,风险比0.54,95%CI 0.27-0.999)。
  • 大出血两组相似(0.8% vs 1.0%)。
  • 验证队列中,早期组(n=547)与晚期组(n=1483)缺血性卒中(2.4% vs 2.2%)和颅内出血(0.2% vs 0.6%)均相似。

关键数值与推荐

  • 短暂性脑缺血发作后中位2天启动直接口服抗凝药。
  • 轻型卒中(美国国立卫生研究院卒中量表0-7分)后中位3天启动。
  • 中型卒中(8-15分)后中位4天启动。
  • 重型卒中(≥16分)后中位5天启动。
  • 早期组定义为各亚组中早于中位启动天数启动直接口服抗凝药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The "1-3-6-12-day rule" for starting direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation after acute ischemic stroke or transient ischemic attack recommends timings that may be later than used in clinical practice. We investigated more practical optimal timing of DOAC initiation according to stroke severity. METHODS: The combined data of prospective registries in Japan, Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-nonvalvular atrial fibrillation (September 2011 to March 2014) and RELAXED (February 2014 to April 2016) were used. Patients were divided into transient ischemic attack and 3 stroke subgroups by the National Institutes of Health Stroke Scale score: mild (0-7), moderate (8-15), and severe (≥16). The early treatment group was defined as patients starting DOACs earlier than the median initiation day in each subgroup. Outcomes included a composite of recurrent stroke or systemic embolism, ischemic stroke, and severe bleeding within 90 days. Six European prospective registries were used for validation. RESULTS: In the 1797 derivation cohort patients, DOACs were started at median 2 days after transient ischemic attack and 3, 4, and 5 days after mild, moderate, and severe strokes, respectively. Stroke or systemic embolism was less common in Early Group (n=785)-initiating DOACS within 1, 2, 3, and 4 days, respectively-than Late Group (n=1012) (1.9% versus 3.9%; adjusted hazard ratio, 0.50 [95% CI, 0.27-0.89]), as was ischemic stroke (1.7% versus 3.2%, 0.54 [0.27-0.999]). Major bleeding was similarly common in the 2 groups (0.8% versus 1.0%). On validation, both ischemic stroke (2.4% versus 2.2%) and intracranial hemorrhage (0.2% versus 0.6%) were similarly common in Early (n=547) and Late (n=1483) Groups defined using derivation data. CONCLUSIONS: In Japanese and European populations, early DOAC initiation within 1, 2, 3, or 4 days according to stroke severity seemed to be feasible to decrease the risk of recurrent stroke or systemic embolism and no increase in major bleeding. These findings support ongoing randomized trials to better establish the optimal timing of DOAC initiation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kimura S, Toyoda K, Yoshimura S, et al. Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke. 2022. PMID: 35105180. doi:10.1161/STROKEAHA.121.036695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。